Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today ...

Serum samples for anti-panitumumab antibody testing were collected from mCRC patients enrolled in 4 panitumumab clinical trials (20050184, 20060277, 20050181, and 20050203). Patients in these ...

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...

The first sa-mRNA vaccine to reach any market was Gennova Biopharmaceuticals' Gemcovac, which was launched in India in 2022 ...

The Netherlands Immunogenicity of adalimumab could impair important treatment outcome parameters in patients with rheumatoid arthritis (RA). Patients who developed antiadalimumab antibodies (AAA) ...

Version of Record: This is the final version of the article.

The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...

The licensure of new PCVs and the acceptance of new PCV schedules will depend on phase II studies of immunogenicity and ... values for the serotype-specific antibodies from this study were ...

Fintel reports that on February 13, 2025, Piper Sandler initiated coverage of Merus N.V. (NasdaqGM:MRUS) with a Overweight ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...